David Parrot

David Parrot is the Chief Financial Officer at Scribe Therapeutics, offering more than 30 years of experience as an Investment Banker advising Life Science Companies on raising capital and executing strategic transactions. David joined Scribe in December 2021 from Barclays, where he served as a managing director and was Head of West Coast Life Science Investment Banking. Before joining Barclays, David spent 11 years at Piper Jaffray as a senior member of the Biotechnology investment banking team. He was previously also a Managing Director at SunTrust Robinson Humphrey and BMO Capital Markets focused on advising private and public biopharma companies.

David earned a BA from Middlebury College and an MBA from the Haas School of Business at the University of California at Berkeley.